 CARLSBAD, Calif., July 29, 2021 PRNewswire -- Ionis Pharmaceuticals, Inc. NASDAQ: IONS, the leader in RNA-targeted therapies, today announced it has completed enrollment of NEURO-TTRansform, the companys Phase 3 study of eplontersen, formerly AKCEA-TTR-LRx, for people with hereditary transthyretin-mediated amyloid polyneuropathy hATTR-PN. 